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ABSTRACT
In this study, we aimed to evaluate the prognostic value of pretreatment blood count values, particularly WBC counts, in patients with 
advanced non-small cell lung cancer (NSCLC). The records of 186 patients with advanced stage (stage IIIB and IV) NSCLC were assessed 
retrospectively. Patients were divided into 3 subgroups according to WBC levels; ≤10000 /mm3 as Group 1, >10000 and ≤15000/mm3 as 
Group 2 and >15000/mm3 as Group 3. Patient and tumor characteristics as well as outcomes in terms of overall survival (OS) were evalu-
ated. Median OS was 13.3 months in the whole population, 25.7 months in stage IIIB and 8.9 months in stage IV patients. According to the 
pretreatment leukocyte values, median OS was 17.9 months in Group 1, 11.2 months in Group 2 and 8.4 months in Group 3 (p= 0.003). 
Median OS values in WBC groups according to stages IIIB and IV were significantly different (p< 0.001). In multivariate analyses, ECOG-PS 
2 or 3, stage IV disease, anemia and high WBC levels were associated with poorer OS. In this study, higher pretreatment WBC levels were 
associated with poorer OS in patients with advanced stage NSCLC. Pretreatment WBC counts may represent a simple prognostic factor 
and may aid in tailoring treatment in patients with advanced NSCLC.
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ÖZET
İleri Evre Küçük Hücreli Dışı Akciğer Kanserinde Hematolojik Parametreler ve Sağkalım İlişkisi
Çalışmamızda, ileri evre küçük hücreli dışı akciğer karsinomu tanısı ile takip ve tedavisi yapılmış olan vakalarda tanı anındaki hematolojik par-
ametreler özellikle de artan beyaz küre değerleri ile sağkalım arasındaki ilişkinin değerlendirilmesi amaçlanmıştır. Evre 3B ve 4 küçük hücreli 
dışı akciğer karsinomu tanısı almış toplam 186 vakanın dosyaları retrospektif olarak değerlendirildi. Hastalar başlangıç lökosit değerlerine 
göre 3 alt gruba ayrıldı; toplam lökosit sayısı ≤10000 /mm3 Grup 1, 10000-≤15000/mm3 Grup 2, >15000  Grup 3. Hasta ve tümör özel-
liklerine ek olarak hematolojik parametreler ile genel sağkalım ilişkisi değerlendirildi. Ortanca sağkalım tüm hasta grubunda 13,3 ay; evre IIIB 
hastalarda 25,7 ay ve evre IV olanlarda 8,9 ay olarak hesaplandı. Tedavi öncesi lökosit değerlerine göre Grup 1’de ortanca sağkalım 17,9 
ay, Grup 2’de 11,2 ay, Grup 3’te ise 8,4 ay idi (p= 0.003). Evreye göre lökosit gruplarının sağkalımları arasında da anlamlı farklılık mevcuttu 
(p< 0.001). Çok değişkenli analizde ECOG-PS 2-3, evre IV hastalık ve tanıdaki hemoglobin ve lökosit değerleri ile sağkalım arasında anlamlı 
ilişki saptandı. Çalışmamızda tanı anındaki yüksek beyaz küre değerlerinin ileri evre küçük hücreli dışı akciğer karsinomunda sağkalım üzer-
inde olumsuz etkisi gösterilmiştir. İleri evre vakalarda tanı anındaki lökosit sayısı, tedavi planı yapılırken yol gösterebilecek basit ve pratik bir 
prognostik faktör olarak değerlendirilebilir.   
Anahtar Kelimeler:  Anemi, Lökositoz, Küçük hücreli dışı akciğer kanseri, Sağkalım, Trombositoz
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INTRODUCTION 
Lung cancer is still the leading cause of cancer-re-
lated death worldwide.1 Five years’ survival is about 
15.9%.2 Non small cell lung cancer (NSCLC) ac-
counts for about 85% of all lung cancer cases. The 
majority of NSCLC patients are diagnosed at ad-
vanced stage, only about 15-20% being early stage at 
diagnosis. Recurrence risk is high even in early stage 
disease.3 Best defined prognostic factors for advanced 
NSCLC are disease stage, ECOG performance sta-
tus (PS), gender and the presence of weight loss.4,5 
Prognosis of patients with advanced disease is mostly 
ominous but also variable among different individu-
als, therefore recent studies began to search for new 
prognostic factors.6,7 At present, most research has fo-
cused on genetic predictive and/or prognostic factors 
such as EGFR, bcl-2 and K-ras mutations, ERCC-1 
and RRM-1 expression, EML4-ALK translocation, 
most of which are not applicable in many centers and 
are often expensive. 
Increased white blood cell (WBC) count can be found 
in patients with cancer either at the time of diagno-
sis or during follow-up period and can be secondary 
to infections, chronic steroid usage or bone marrow 
metastases.8 However, patients with NSCLC may 
sometimes have leukocytosis distinct from these 
conditions, described as tumor-related leucocytosis, 
a condition which is caused mainly by unregulated 
autonomous production of hematopoietic cytokines 
such as G-CSF, GM-CSF and IL-6.9,10 Previous 
studies showed leukocytosis to be secondary to the 
production of G-CSF by the tumor, and this was an 
epiphenomenon of the biologic aggressiveness of the 
tumor.11 The prognostic importance of blood count 
findings were evaluated by some large series previ-
ously but the results were contradictory.12-14
In this study, we aimed to evaluate the prognostic 
value of pretreatment blood count values, particularly 
WBC counts, in patients with advanced NSCLC.
MATERIAL AND METHODS
The records of 220 patients with histologically con-
firmed stage IIIB and IV NSCLC were reviewed 
retrospectively. Patients with active infection, bone 
marrow metastases or history of steroid use at the 
time of diagnosis were excluded. In total 186 patients 
were included in this study. Patient and tumor char-
acteristics including ECOG-PS and disease stage as 
well as pre-treatment WBC count, hemoglobin (Hb) 
and platelet (plt) levels were recorded. Patients were 
grouped as anemic if Hb level was <12 g/dl for fe-
males and <13 g/dl for males. Thrombocytosis was 
defined as platelet count >373000/mm3 according to 
the reference limits in our laboratory. 
Shapiro-Wilk’s test results, histogram and q-q plots 
were examined to assess the data homogeneity. One-
way analysis of variance, Kruskal-Wallis H test and 
Mann-Whitney U tests were used to compare differ-
ences between continous variables and Chi-Square 
analysis were used to compare differences between 
categorical variables. Values are expressed as n(%), 
mean ±SD or median(25th -75th percentiles). Moreo-
ver, Kaplan-Meier curves were drawn to obtain sur-
vival probabilities and log rank test was used to com-
pare these curves between groups. Univariate and 
multiple cox regression analysis were also applied 
and hazard ratios were calculated with 95% confi-
dence intervals. For overdispersed variables, z-scores 
were calculated and these transformed variables were 
used instead of raw values. Significant variables at p< 
0.25 were included to multiple model and backward 
stepwise selection was applied at 0.10 stringency lev-
el. Analyses were conducted using R 2.15.2 software. 
P< 0.05 was considered statistically significant.  
 
RESULTS
Median age was 63 (range 37-88). Twenty-five 
(13.4%) patients were female and 161 (86.6%) were 
male. A history of smoking was present in 85.7% of 
the patients. Histological subtype was adenocarcino-
mas in 64 patients (34.4%), squamous cell carcinoma 
in 85 patients (45.7%), unspecified (NOS) type in 
31 patients (16.7%). The remaining 5 cases (2.7%) 
had large cell and bronchoalvelolar subtype. Disease 
stage was IIIB in 66 (35.5%) and IV in 120 patients 
(64.5%). 
Median OS was 13.3 months (95% CI: 10.1-16.6) 
in the whole population. Overall survival was sig-
nificantly longer in patients with stage IIIB dis-
ease than those with stage IV disease  [25.7 months 
(95%CI:14.9-36.5) vs 8.9 months (95% CI: 6.9-10.9), 
respectively, p< 0.001]. 
ECOG-PS of the patients were 0 in 56 (30.1%), 1 in 
86 (46.2%), 2 in 31 (16.7%) and 3 in 13 (7.0%) of the 
patients at diagnosis. Median OS was 18.8 months for 
the patients with a PS of 0, 15.4 months for PS of 1, 
4.6 months for PS of 2 and 4.0 months for PS of 3. 
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The difference in OS between ECOG-PS groups was 
statistically significant (p< 0.001). 
Pretreatment WBC, hemoglobin and platelet levels 
for stages IIIB and IV patients are shown in Table 1. 
WBC levels were significantly higher in patients with 
stage IVdisease than those with stage IIIB disease (p= 
0.034). Hemoglobin and platelet levels were similar 
in stage IIIB and IV patients. 
For further analysis the patients were divided into 3 
subgroups according to WBC levels; ≤10000 /mm3 as 
Group 1 (n: 82), >10000 and ≤15000/mm3 as Group 
2 (n:80) and >15000/mm3 as Group 3 (n= 24). There 
were no significant differences between these groups 
in terms of variables that may affect survival as gen-
der, performance status, histological subtype and 
stage (p values were 0.334, 0.498, 0.384 and 0.162 
respectively). Median OS in these WBC groups 
were 17.9 months (95% CI:13.2-22.7) in Group 1, 
11.2 months (95% CI: 5.8-16.6) in Group 2 and 8.4 
months (95% CI: 4.3-12.5) in Group 3. The differ-
ence between groups was statistically significant (p= 
0.003) (Figure 1). 
Median overall survival values in WBC groups ac-
cording to stages IIIB and IV are shown in Table 2. 
There was a trend towards longer OS in patients with 
lower WBC counts within each stage group, although 
the difference was not statistically significant (Figure 
2a and 2b). The poorest survivals were detected in the 
stage IV patients with higher WBC levels, median OS 
was 5.7 months in patients with WBC levels >15000/
mm3, whereas it was 12.1 months for patients with 
normal WBC levels <10000/mm3 (p= 0.066). (Figure 
2b)  
Median OS was 10.6 months (95% CI: 5.9-15.3) in 
patients with anemia (n= 80), whereas it was 17.3 
months (95% CI:13.5-21.0) in those without (n= 106) 
anemia (p= 0.204). Thrombocytosis was detected in 
50 (26.9%) of the cases. Patients with thrombocytosis 
had lower OS [8.5 months (95% CI: 7.9-9.1)] than 
those without [15.6 months (95% CI:11.6-19.6)] (p= 
0.048). 
In univariate analyses age, ECOG-PS of 2 or 3, stage 
IV disease, pretreatment hemoglobin and WBC levels 
were significant for survival. In multivariate analyses, 
ECOG-PS of 2 or 3, stage IV disease, pretreatment 
low hemoglobin and high WBC levels were found to 
be independently associated with poorer OS (Table 
3).
Table 1. Median levels of pretreatment blood counts
                        Stage  p
 IIIB IV
WBC 9850 (7777-12000) 10800 (8700-13770) 0.034
Hb 13.25 (11.47-14.20) 12.90 (11.52-14.20) 0.819
Plt 295000 (232750-351750) 306000 (240500-427250) 0.206
Table 2. Median survival values in WBC groups according to stages
WBC groups           Median survival (months)
 Stage IIIB Stage IV
1 (≤10000 /mm3) 39.77 (6.48-73.06) 12.1 (9.77-14.50)
2 (10001-≤15000/mm3) 19.67 (14.92-24.42) 8.5 (6.71-10.29)
3 (>15000/mm3) 10.43 (4.86- 15.80) 5.70 (1.95-9.45)
Figure 1. Overall survivals in WBC groups
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DISCUSSION
In this study, we found that along with classical prog-
nostic factors including disease stage and ECOG-PS, 
lower hb levels and higher WBC counts were inde-
pendently associated with poorer OS in patients with 
stage IIIB-IV NSCLC. Median OS was 25.7 months 
in stage IIIB and 8.9 months in stage IV disease in our 
study, consistent with the literature. 
Prognostic value of various clinical and laboratory pa-
rameters were assessed in previous studies in patients 
with NSCLC. Hoang et al analysed prognostic factors 
in chemo-naive advanced NSCLC patients to build a 
nomogram to predict 1- and 2-year survivals. Pres-
ence of skin or liver metastases, lower performance 
status, loss of appetite and presence of more than 3 
metastatic sites were all found to be poor prognostic 
factors that predicted 1- and 2-year survival. Hemato-
logical parameters were not evaluated.15 Similarly in 
our study, stage IV and poor performance status were 
shown to be associated with shorter OS. Kasuga et 
al. investigated the prognostic value of leucocytosis 
among 227 patients with stage I-IV NSCLC. Patients 
with leukocytosis at diagnosis or at any time on fol-
low-up had shorter OS than those without (4.6 vs 20.8 
months,  p< 0.001). They also examined the serum 
levels of G-CSF, GM-CSF and IL-6  and found that 
29 out of 32 patients with tumor related leucocytosis 
had high levels of at least one of the cytokines. The 
frequency of tumor related leucocytosis was highest 
in large cell group compared with adeno and squa-
mous group (54.5%, 11.7% and 20% respectively).16 
In our study, although the number of patients with 
large cell carcinoma was small, the frequency of tu-
mor related leucocytosis was also highest in large 
cell group (75%). However no association was found 
between any histopathological subtype and pretreat-
ment WBC levels (p= 0.387). 
Mandrekar et al. performed a pooled data set of 9 
North Central CancerTreatment Group trials in 1053 
advanced NSCLC patients to examine the impact of 
pretreatment blood levels (creatinine, hemoglobin, 
WBC and platelet counts) and other demographical 
factors on OS and time to progression. Multivariate 
analysis revealed that stage IV disease (p= 0.03), 
body mass index<18.5 (p= 0.0007), ECOG-PS>0 (p< 
0.0001), low hemoglobin levels (p< 0.0001) and high 
WBC counts (p= 0.0001) were poor prognostic fac-
tors for both OS and time to progression. In patients 
with leucocytosis, the prognosis was particularly 
poor for stage IV patients, however such a prognostic 
value in stage IIIB patients was not clearly defined. 
Presence of anemia and thrombocytosis were signifi-
cant for both TTP and overall survival in univariate 
setting, but in multivariate analysis while anemia was 
still significant, presence of thrombocytosis was not 
found to be correlated with survival values.17 In our 
study, although anemia and higher pretreatment leu-
cocyte levels were associated with poorer survival in 
the whole group, this association could not be shown 
within each stage group, possibly due to type-II error. 
Also presence of thrombocytosis was not detected 
to be significant for survival values in multivariate 
analysis. 
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Figure 2. Survivals according to WBC groups, in stage IIIB (A) and in stage IV (B)
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Paesmans et al studied prognostic factors for survival 
in 1052 advanced NSCLC patients. They confirmed 
their results by application of recursive partitioning 
and amalgamation algorithms (RECPAM) and classi-
fied patients into 4 subgroups according to estimated 
median survival times. In this classification, only 
abnormal WBC and neutrophil counts were shown 
to be poor prognostic for survival. Thrombocytosis 
was not shown to be correlated with survival values.14 
However in the study by Tomita et al. it was shown 
that the presence of preoperative anemia, leucocyto-
sis and thrombocytosis, when found together, was as-
sociated with worse 5 year survival rates compared 
with those without any of these abnormal cell counts 
in resectable NSCLC patients (5 year survivals 25.0% 
vs 78.2%, respectively).18 Another study showed that 
presence of anemia alone was associated with de-
creased relapse free survival and OS (p= 0.02 and 
0.026 respectively) for NSCLC patients who were 
treated by definitive surgery and who did not receive 
any (neo)adjuvant treatment.3
In a recent study, the prognostic value of pretreatment 
hemoglobin, WBC and platelet levels were investi-
gated in a cohort of patients with stage I-IV NSCLC 
who received curatively intended radiotherapy. Both 
seperately and all possible combinations of abnormal 
results of these 3 blood parameters were associated 
with poor prognosis, and it was shown that when 
more than one marker was abnormal, the negative 
prognostic value increased noticeably. Median sur-
vivals were 16 months for patients without abnormal 
levels in any of these 3 blood counts and 8 months 
for those with abnormal results in all 3 counts (p< 
0.0001). It was concluded that standard haematologi-
cal variables might be used in the patient-based deci-
sion making regarding treatment.19  
Besides the presence of tumor related leucocytosis, 
a pooled analysis of an Italian group data from about 
Table 3. Univariate and multivariate cox regression results
VARIABLES Univariate p Multivariate p
 HR (95%CI)  HR (95%CI)
Age 1.22 (1.01-1.46) 0.035 – –
Gender
  Male 1.00 – – –
  Female 1.19(0.71-1.99) 0.509 – – 
ECOG-PS
  0 1.00 – 1.00 –
  1 1.18 (0.76-1.82) 0.463 1.16 (0.73-1.84) 0.543
  2 5.00 (2.84-8.80) <0.001 3.49 (1.88-6.48) <0.001
  3 3.92 (2.06-7.46) <0.001 5.99 (3.01-11.91) <0.001
Stage
  IIIB 1.00 – 1.00 –
  IV 2.54 (1.72-3.78) <0.001 1.87 (1.20-2.91) 0.006
Smoking
  No 1.00 – – –
  Yes 0.90 (0.55-1.47) 0.671 – – 
Subtype
  Nos 1.00 – – –
  Adeno 0.77 (0.47-1.28) 0.312 – –
  Squamous 0.81 (0.51-1.31) 0.397 – – 
WBC 1.54 (1.27-1.88) <0.001 1.40 (1.14-1.73) 0.001
Hemoglobin 0.93 (0.84-1.02) 0.01 0.90 (0.82-0.99) 0.029
Plt 1.16 (0.99-1.34) 0.061 – –
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1300 advanced stage NSCLC patients described the 
prognostic role of mild and severe chemotherapy in-
duced neutropenia. In this analysis, 53% of the cases 
had experienced at least one episode of neutrope-
nia of any grade. Mild and severe neutropenia were 
found to be significant prognostic factors with hazard 
ratios of death as 0.74 (95% CI: 0.56-0.98) and 0.65 
(95% CI: 0.46-0.93) respectively.20 Also Pallis et al. 
suggested that chemotherapy induced neutropenia 
was an independent prognopstic factor for survival.21 
Later Maione et al. hypothesized if the prognostic 
value of chemotherapy induced neutropenia being af-
fected by the presence of tumor related leucocytosis 
and if these two groups were in fact the representa-
tives of the same population.22 But this is still an era 
to be lightened by prospective trials.
In conclusion, hematological parameters including 
WBC counts or hb levels can be used as prognos-
tic factors in patients with advanced NSCLC. Being 
simple, cheap and widely available, these factors may 
aid in tailoring treatment according to subgroups or 
in risk stratification in clinical trials. In the light of 
these findings, future prospective trials evaluating 
the predictive value of these blood parameters on the 
chemotherapy regimens may be useful for tailoring 
the treatment in each case. 
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